Thomas Semrad MD MAS

Medical Oncologist Gene Upshaw Tahoe Forest Cancer Center Associate Clinical Professor (WOS) of Hematology/Oncology UC Davis Medical Center

Join to View Full Profile

10121 Pine AveTruckee, CA 96161
Phone+1 530-582-6450

Education & Training

University of California Davis HealthFellowship, Hematology and Medical Oncology, 2007 - 2010
University of California Davis HealthResidency, Internal Medicine, 2004 - 2007
Rush Medical College of Rush University Medical CenterClass of 2004

Certifications & Licensure

CA State Medical License 2005 - 2025
NV State Medical License 2023 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Completed
Phase 1, Phase 2
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 2, Phase 3
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Start of enrollment: 2013 Feb 01
Completed
Phase 2
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
COMPLETED
PHASE2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
ACTIVE_NOT_RECRUITING
PHASE3
Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer Start of enrollment: 2013 Aug 01
Completed
Phase 1
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer Start of enrollment: 2014 Aug 29
COMPLETED
PHASE1
Join now to see all

Publications & Presentations

PubMed

1 citations
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors.
Sonia M Abuzakhm, Vineeth Sukrithan, Briant Fruth, Rui Qin, Jonathan Strosberg
Endocrine-Related Cancer. 2023-11-01
74 citations
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Manish A Shah, Erin B Kennedy, Ashley E Alarcon-Rozas, Thierry Alcindor, Angela N Bartley
Journal of Clinical Oncology. 2023-03-01
5 citations
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer.
Justin A Chen, Jasmine C Huynh, Chun-Yi Wu, Ai-Ming Yu, Karen Matsukuma
Cancer Chemotherapy and Pharmacology. 2022-09-01

Thomas Semrad MD MAS

Dr. Semrad is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.